By Dr. Paul Nunzio DeSantis, Pharm.D : Abbvie's (NYSE: ABBV )'s proactive and strategic efforts throughout 2014 are undoubtedly welcome measures by shareholders who are increasingly weary of ABBV's dependence on Humira as patent expiration arrives in 2016. We specifically support their £53.80 bid
By Stephen Simpson, CFA : By just about any reasonable standard, Roche (OTCQX: RHHBY ) is an exceptional pharmaceutical and diagnostics company. Through internal efforts and acquisitions large and small (particularly Genentech), Roche has become one of the largest players in oncology, with ...
Idenix (NASDAQ: IDIX ) and Intermune (NASDAQ: ITMN ) . Why so many pharma deals ..... the same time, we learned that Intermune , a Brisbane, California-based ..... gobbled up by a larger rival. Intermune has been developing drugs to
s GSK acquisition in 2012 of Human Genome Sciences and Roche's RHHBY recent announcement of its plans to acquire InterMune ITMN . Given Big Pharma's flush balance sheets, we expect more biotechs to be acquired by large pharmaceutical firms
GlaxoSmithKline's GSK acquisition in 2012 of Human Genome Sciences and Roche's recent announcement of its plans to acquire InterMune ITMN . Given Big Pharma's flush balance sheets, we expect more biotechs to be acquired by large pharmaceutical firms
click to enlarge) Yesterday, Roche acquired InterMune (NASDAQ: ITMN ) in an over $8 billion deal with an almost 40 ..... premium. The main attraction for Roche of acquiring InterMune is the company's drug for idiopathic pulmonary
affirmed at 'F1+'. The Outlook is 'Stable'. A full list of rating actions is available at the end of this commentary. The rating affirmation follows Roche's proposed tender offer to acquire 100% of US-based biotech company InterMune
suggest interested parties could include Shire (NASDAQ: SHPG ) and GlaxoSmithKline (NYSE: GSK ); the report suggests the recent premium paid for InterMune could put a valuation of at least $40/share on TKMR. Post your comment!
(Reuters) - Roche Holding AG's planned $8 billion purchase of InterMune Inc is centered around hopes for blockbuster sales of its lung drug, but the smaller company's development pipeline may end up giving the Swiss drugmaker a far bigger bang for its buck.
leverage existing efforts in pulmonary/respiratory disease, Roche has stepped up with an expensive bid for InterMune (NASDAQ: ITMN ). Roche Finally Makes Its Move Even though Roche has been somewhat active on the M&A front (recently acquiring